Systemic Complement Activation Levels in Stargardt Disease

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2021 Jun 25

PMID 34170959

Citations 4

Authors

Patty P A Dhooge

Esmee H Runhart

Catherina H Z Li

Corrie M de Kat Angelino

Carel B Hoyng

Renate G van der Molen

Anneke I den Hollander

Affiliations

Soon will be listed here.

Abstract

Purpose: Preclinical research provides evidence for the complement system as a potential common pathway in Stargardt disease (STGD1) and age-related macular degeneration (AMD) leading to retinal pigment epithelium (RPE) loss. However, systemic complement activation has not yet been assessed in STGD1 patients. We conducted a cross-sectional case-control study to assess systemic complement activation in STGD1 patients and its association with disease severity.

Methods: Systemic concentrations of complement component C3 and its degradation product C3d were compared between 80 STGD1 patients and 80 controls that were frequency matched for age and sex. The C3d/C3 ratio was used as parameter of systemic complement activation. Within the STGD1 cohort, we additionally examined the association between the C3d/C3 ratio, demographic and behavioural factors (age, sex, smoking and BMI), and measures of disease severity (age at onset, visual acuity, and area of atrophy).

Results: The C3d/C3 ratio did not significantly differ between patients (mean C3d/C3 ratio 3.5±1.4) and controls (mean C3d/C3 ratio 3.6±1.0), mean difference -0.156 (p = 0.804, independent samples t-test). The overall effect size was 8% (95% confidence interval, 3-15%). Elevated C3d/C3 ratios (>8.1) were found in three patients who all had a concomitant inflammatory condition at the time of blood draw. Within the patient cohort, C3 levels were associated with sex (mean difference -134, p = 0.001, independent samples t-test) and BMI (correlation coefficient 0.463, p<0.001, Spearman's Correlation).

Conclusions: Systemic complement levels were not elevated in STGD1 patients compared to age and sex matched controls and was not associated with STGD1 severity. Considering the continued absent proof of a systemic contribution of the complement system to RPE loss in STGD1 patients, we hypothesize that complement activation in STGD1 is more likely a local process. In light of upcoming complement-targeted therapies, further studies are needed that measure complement levels in the eye of STGD1 patients.

Citing Articles

Polyunsaturated Lipids in the Light-Exposed and Prooxidant Retinal Environment.

Longoni B, Demontis G Antioxidants (Basel). 2023; 12(3).

PMID: 36978865 PMC: 10044808. DOI: 10.3390/antiox12030617.

Pitfalls in complement analysis: A systematic literature review of assessing complement activation.

Brandwijk R, Michels M, van Rossum M, de Nooijer A, Nilsson P, de Bruin W Front Immunol. 2022; 13:1007102.

PMID: 36330514 PMC: 9623276. DOI: 10.3389/fimmu.2022.1007102.

Clinical Prognostic Implications of Wnt Hub Genes Expression in Medulloblastoma.

Martins-da-Silva A, Baroni M, Salomao K, das Chagas P, Bonfim-Silva R, Geron L Cell Mol Neurobiol. 2022; 43(2):813-826.

PMID: 35366170 PMC: 11415171. DOI: 10.1007/s10571-022-01217-4.

The Next Generation of Molecular and Cellular Therapeutics for Inherited Retinal Disease.

Martinez Velazquez L, Ballios B Int J Mol Sci. 2021; 22(21).

PMID: 34768969 PMC: 8583900. DOI: 10.3390/ijms222111542.

References

Kersten E, Paun C, Schellevis R, Hoyng C, Delcourt C, Lengyel I . Systemic and ocular fluid compounds as potential biomarkers in age-related macular degeneration. Surv Ophthalmol. 2017; 63(1):9-39. DOI: 10.1016/j.survophthal.2017.05.003. View

Valkenburg D, Runhart E, Bax N, Liefers B, Lambertus S, Sanchez C . Highly Variable Disease Courses in Siblings with Stargardt Disease. Ophthalmology. 2019; 126(12):1712-1721. DOI: 10.1016/j.ophtha.2019.07.010. View

Smailhodzic D, Klaver C, Klevering B, Boon C, Groenewoud J, Kirchhof B . Risk alleles in CFH and ARMS2 are independently associated with systemic complement activation in age-related macular degeneration. Ophthalmology. 2011; 119(2):339-46. DOI: 10.1016/j.ophtha.2011.07.056. View

Cheng X, He D, Liao C, Lin S, Tang L, Wang Y . IL-1/IL-1R signaling induced by all-trans-retinal contributes to complement alternative pathway activation in retinal pigment epithelium. J Cell Physiol. 2020; 236(5):3660-3674. DOI: 10.1002/jcp.30103. View

de Jong P . Age-related macular degeneration. N Engl J Med. 2006; 355(14):1474-85. DOI: 10.1056/NEJMra062326. View

Warwick A, Khandhadia S, Ennis S, Lotery A . Age-Related Macular Degeneration: A Disease of Systemic or Local Complement Dysregulation?. J Clin Med. 2015; 3(4):1234-57. PMC: 4470180. DOI: 10.3390/jcm3041234. View

Reynolds R, Hartnett M, Atkinson J, Giclas P, Rosner B, Seddon J . Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci. 2009; 50(12):5818-27. PMC: 2826794. DOI: 10.1167/iovs.09-3928. View

Kuehlewein L, Hariri A, Ho A, Dustin L, Wolfson Y, Strauss R . COMPARISON OF MANUAL AND SEMIAUTOMATED FUNDUS AUTOFLUORESCENCE ANALYSIS OF MACULAR ATROPHY IN STARGARDT DISEASE PHENOTYPE. Retina. 2015; 36(6):1216-21. DOI: 10.1097/IAE.0000000000000870. View

Radu R, Hu J, Yuan Q, Welch D, Makshanoff J, Lloyd M . Complement system dysregulation and inflammation in the retinal pigment epithelium of a mouse model for Stargardt macular degeneration. J Biol Chem. 2011; 286(21):18593-601. PMC: 3099675. DOI: 10.1074/jbc.M110.191866. View

10.

Allikmets R, Singh N, Sun H, Shroyer N, Hutchinson A, Chidambaram A . A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet. 1997; 15(3):236-46. DOI: 10.1038/ng0397-236. View

11.

Boon C, van Schooneveld M, den Hollander A, van Lith-Verhoeven J, Zonneveld-Vrieling M, Theelen T . Mutations in the peripherin/RDS gene are an important cause of multifocal pattern dystrophy simulating STGD1/fundus flavimaculatus. Br J Ophthalmol. 2007; 91(11):1504-11. PMC: 2095453. DOI: 10.1136/bjo.2007.115659. View

12.

Scholl H, Charbel Issa P, Walier M, Janzer S, Pollok-Kopp B, Borncke F . Systemic complement activation in age-related macular degeneration. PLoS One. 2008; 3(7):e2593. PMC: 2440421. DOI: 10.1371/journal.pone.0002593. View

13.

Geerlings M, de Jong E, den Hollander A . The complement system in age-related macular degeneration: A review of rare genetic variants and implications for personalized treatment. Mol Immunol. 2016; 84:65-76. PMC: 5380947. DOI: 10.1016/j.molimm.2016.11.016. View

14.

Hageman G, Anderson D, Johnson L, Hancox L, Taiber A, Hardisty L . A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005; 102(20):7227-32. PMC: 1088171. DOI: 10.1073/pnas.0501536102. View

15.

Hu J, Pauer G, Hagstrom S, Bok D, DeBenedictis M, Bonilha V . Evidence of complement dysregulation in outer retina of Stargardt disease donor eyes. Redox Biol. 2020; 37:101787. PMC: 7767765. DOI: 10.1016/j.redox.2020.101787. View

16.

Fritsche L, Igl W, Cooke Bailey J, Grassmann F, Sengupta S, Bragg-Gresham J . A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2015; 48(2):134-43. PMC: 4745342. DOI: 10.1038/ng.3448. View

17.

Yuan X, Gu X, Crabb J, Yue X, Shadrach K, Hollyfield J . Quantitative proteomics: comparison of the macular Bruch membrane/choroid complex from age-related macular degeneration and normal eyes. Mol Cell Proteomics. 2010; 9(6):1031-46. PMC: 2877969. DOI: 10.1074/mcp.M900523-MCP200. View

18.

Branten A, Kock-Jansen M, Klasen I, Wetzels J . Urinary excretion of complement C3d in patients with renal diseases. Eur J Clin Invest. 2003; 33(6):449-56. DOI: 10.1046/j.1365-2362.2003.01153.x. View

19.

Heesterbeek T, Lechanteur Y, Lores-Motta L, Schick T, Daha M, Altay L . Complement Activation Levels Are Related to Disease Stage in AMD. Invest Ophthalmol Vis Sci. 2020; 61(3):18. PMC: 7401663. DOI: 10.1167/iovs.61.3.18. View

20.

Zhou J, Jang Y, Kim S, Sparrow J . Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc Natl Acad Sci U S A. 2006; 103(44):16182-7. PMC: 1637557. DOI: 10.1073/pnas.0604255103. View